OpenURL Connection Search

Select item for more details and to access through your institution.

The Na+,K+,2Cl−-cotransport system in HeLa cells: Aspects of its physiological regulation.
Published in:
Journal of Cellular Physiology, 1990, v. 145, n. 2, p. 253, doi. 10.1002/jcp.1041450209
By:
- Kort, Jens J.;
- Koch, Gebhard
Publication type:
Article
The Na+, K+, 2Cl−-cotransport system in HeLa cells and HeLa cell mutants exhibiting an altered efflux pathway.
Published in:
Journal of Cellular Physiology, 1989, v. 141, n. 1, p. 181, doi. 10.1002/jcp.1041410126
By:
- Kort, Jens J.;
- Koch, Gebhard
Publication type:
Article
Drug‐Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
Published in:
Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 779, doi. 10.1002/cpdd.671
By:
- Kosloski, Matthew P.;
- Zhao, Weihan;
- Li, Hong;
- Pugatch, David;
- Asatryan, Armen;
- Kort, Jens;
- Mensa, Federico J.;
- Liu, Wei
Publication type:
Article
Diagnosis of Latent Tuberculosis Infection with T-SPOT. TB in a Predominantly Immigrant Population with Rheumatologic Disorders.
Published in:
Lung, 2015, v. 193, n. 1, p. 3, doi. 10.1007/s00408-014-9655-9
By:
- Escalante, Patricio;
- Kooda, Kirstin;
- Khan, Rizwana;
- Aye, San;
- Christianakis, Stratos;
- Arkfeld, Daniel;
- Ehresmann, Glenn;
- Kort, Jens;
- Jones, Brenda
Publication type:
Article
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Published in:
Liver International, 2016, v. 36, n. 8, p. 1125, doi. 10.1111/liv.13067
By:
- Poordad, Fred;
- Landis, Charles S.;
- Asatryan, Armen;
- Jackson, Daniel F.;
- Ng, Teresa I.;
- Fu, Bo;
- Lin, Chih ‐ Wei;
- Yao, Betty;
- Kort, Jens
Publication type:
Article
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
Published in:
European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 217, doi. 10.1007/s00228-018-2576-4
By:
- Kosloski, Matthew P.;
- Liu, Wei;
- Wang, Haoyu;
- Pugatch, David;
- Mensa, Federico J.;
- Gane, Edward;
- Lawitz, Eric;
- Marbury, Thomas C.;
- Preston, Richard A.;
- Kort, Jens
Publication type:
Article
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Published in:
Viruses (1999-4915), 2018, v. 10, n. 9, p. 462, doi. 10.3390/v10090462
By:
- Ng, Teresa I.;
- Pilot-Matias, Tami;
- Tripathi, Rakesh;
- Schnell, Gretja;
- Krishnan, Preethi;
- Reisch, Thomas;
- Beyer, Jill;
- Dekhtyar, Tatyana;
- Irvin, Michelle;
- Lu, Liangjun;
- Asatryan, Armen;
- Campbell, Andrew;
- Yao, Betty;
- Lovell, Sandra;
- Mensa, Federico;
- Lawitz, Eric J.;
- Kort, Jens;
- Collins, Christine
Publication type:
Article
Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir.
Published in:
Clinical Infectious Diseases, 2014, v. 59, n. 10, p. 1420, doi. 10.1093/cid/ciu616
By:
- Sabo, John P.;
- Kort, Jens;
- Ballow, Charles;
- Haschke, Manuel;
- Battegay, Manuel;
- Fuhr, Rainard;
- Girlich, Birgit;
- Schobelock, Michael;
- Feifel, Ulrich;
- Lang, Benjamin;
- Li, Yongmei;
- Elgadi, Mabrouk
Publication type:
Article
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation.
Published in:
Journal of Clinical Pharmacology, 2015, v. 55, n. 4, p. 467, doi. 10.1002/jcph.436
By:
- Sabo, John P.;
- Kort, Jens;
- Ballow, Charles;
- Kashuba, Angela D.M.;
- Haschke, Manuel;
- Battegay, Manuel;
- Girlich, Birgit;
- Ting, Naitee;
- Lang, Benjamin;
- Zhang, Wei;
- Cooper, Curtis;
- O'Brien, Drané;
- Seibert, Eleanore;
- Chan, Tom S.;
- Tweedie, Donald;
- Li, Yongmei
Publication type:
Article
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Published in:
Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1616, doi. 10.1002/jcph.959
By:
- Lin, Chih‐Wei;
- Dutta, Sandeep;
- Ding, Bifeng;
- Wang, Tianli;
- Zadeikis, Neddie;
- Asatryan, Armen;
- Kort, Jens;
- Campbell, Andrew;
- Podsadecki, Thomas;
- Liu, Wei
Publication type:
Article
Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine.
Published in:
CTS: Clinical & Translational Science, 2023, v. 16, n. 4, p. 593, doi. 10.1111/cts.13471
By:
- Kosloski, Matthew P.;
- Li, Hong;
- Wang, Stanley;
- Mensa, Federico;
- Kort, Jens;
- Liu, Wei
Publication type:
Article
Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu.
Published in:
Clinical Transplantation, 2023, v. 37, n. 4, p. 1, doi. 10.1111/ctr.14926
By:
- Kim, Myung‐Ho;
- Sise, Meghan E.;
- Xu, Min;
- Goldberg, David S.;
- Fontana, Robert J.;
- Kort, Jens J.;
- Alloway, Rita R.;
- Durand, Christine M.;
- Brown, Robert S.;
- Levitsky, Josh;
- Gustafson, Jenna L.;
- Reese, Peter P.;
- Chung, Raymond T.
Publication type:
Article
Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Published in:
2020
By:
- Kosloski, Matthew P;
- Oberoi, Rajneet;
- Wang, Stanley;
- Viani, Rolando M;
- Asatryan, Armen;
- Hu, Beibei;
- Ding, Bifeng;
- Qi, Xin;
- Kim, Elaine J;
- Mensa, Federico;
- Kort, Jens;
- Liu, Wei
Publication type:
journal article
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.
Published in:
2020
By:
- Flamm, Steven L.;
- Kort, Jens;
- Marx, Steven E.;
- Strezewski, John;
- Dylla, Douglas E.;
- Bacon, Bruce;
- Curry, Michael P.;
- Tsai, Naoky;
- Wick, Nicole
Publication type:
journal article

Found: 14

The Na<sup>+</sup>,K<sup>+</sup>,2Cl<sup>−</sup>-cotransport system in HeLa cells: Aspects of its physiological regulation.

The Na<sup>+</sup>, K<sup>+</sup>, 2Cl<sup>−</sup>-cotransport system in HeLa cells and HeLa cell mutants exhibiting an altered efflux pathway.

Drug‐Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.

Diagnosis of Latent Tuberculosis Infection with T-SPOT. TB in a Predominantly Immigrant Population with Rheumatologic Disorders.

High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir.

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation.

Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.

Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine.

Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu.

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.